Roth, Sophie
Berger, Fabian K.
Link, Andreas
Nimmesgern, Anna
Lepper, Philipp M.
Murawski, Niels
Bittenbring, Jörg T.
Becker, Sören L. http://orcid.org/0000-0003-3634-8802
Funding for this research was provided by:
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Article History
Received: 13 July 2020
Accepted: 24 August 2020
First Online: 7 September 2020
Compliance with ethical standards
:
: S. L. Becker has received travel grants and speaker fees from Astellas Pharmaceuticals, Becton Dickinson, Novartis and Pfizer and participated at a Pfizer Advisory Board on ceftazidime/avibactam. In a previous research consortium on tropical infections (NIDIAG, funded by the European Commission), S. L. Becker has collaborated with Coris BioConcept, the manufacturer of the RESIST-4 O.K.N.V. RDT used in the current study, pertaining to diagnostic test development for parasitic diseases. All other authors have nothing to disclose.
: Not applicable.